Skip to main content
. 2024 Jul 23;9(1):e001702. doi: 10.1136/bmjophth-2024-001702

Figure 2. Risk of bias contributions and network geometry for the comparison of anti-VEGF agents for age-related macular degeneration neovascular (BCVA). (A) Risk of bias contributions for the comparison for BCVA. (B) Network geometry for mean change in BCVA. Afli, aflibercept; Beva, bevacizumab; Brolu, brolucizumab; Fari, faricimab; LD, loading dose; PRN, pro re nata; Rani, ranibizumab; T&E treat and extend; VEGF, vascular endothelial growth factor; q4w, q8w, q12w, q16w, injections every 4, 8, 12 and 16 weeks, respectively.

Figure 2